logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: News & Comments

Ionis Pharmaceuticals News About ALS Treatment Attempts

Ionis Pharmaceuticals Dosed First Patients with ION541 for ALS Ionis Pharmaceuticals ( IONS ) announced that the first patients have been dosed with ION541 (also known as BIIB105) - an investigational antisense medicine being developed as a potential therapy to...

Read More

October 22, 2020

0

The U.S. FDA Approves Gilead Sciences Antiviral Veklury® (remdesivir) for COVID-19

Gilead Sciences Veklury® (Remdesivir) was Approved by the US FDA The U.S. FDA approved Gilead Sciences ( GILD ) antiviral drug Veklury® (remdesivir) for COVID-19 infected patients who require hospitalization. Veklury halts the SARS-CoV-2 replication that causes COVID-19. Veklury is...

Read More

October 23, 2020

0

Tracking the News from AstraZeneca About Experimental Vaccine, AZD1222, for COVID-19

News from AstraZeneca About COVID-19 Vaccine, AZD1222 From AstraZeneca ( AZN ) we learned that its COVID-19 vaccine, AZD1222, which is being developed in collaboration with Oxford University, has produced a similar immune response in older and younger adults. A...

Read More

October 26, 2020

0

Halozyme and argenx Most Recent News

Halozyme and argenx Collaboration argenx ( ARGX )   dosed the first subject in phase 1 clinical trial for the safety, pharmacokinetics, and pharmacodynamics of its product efgartigimod plus Halozyme's ( HALO ) drug delivery technology ENHANZE ® . The...

Read More

July 19, 2019

0

Akero Therapeutics' Product Efruxifermin Demonstrates Strong Positive Results in NASH Patients

Akero Therapeutics Efruxifermin Positive Results in NASH Akero Therapeutics ( AKRO ) results of a 16-week analysis of secondary and exploratory endpoints in Phase 2a BALANCED study of its product efruxifermin ( EFX ), formerly known as AKR-001, in patients with...

Read More

July 1, 2020

0

Imminent Announcements of Important Quarterly Results

Important Quarterly Results Announcements Monday, November 2, 2020 at 8:PM ET IVERIC bio IVERIC bio's ( ISEE ) management team will host a live conference call and webcast following the announcement to discuss the Company’s financial results and provide a...

Read More

October 28, 2020

0

RegenxBio Has Good News

RegenxBio License Agreement with Pfizer RegenxBio ( RGNX )   announced a license agreement with  Pfizer ( PFE ). Under the terms of the agreement RegenxBio has granted Pfizer a non-exclusive worldwide license, with rights to sublicense, to RegenxBio's NAV...

Read More

August 1, 2019

0

Rhythm Pharmaceuticals Has Good News. See Also: The Novartis News Story

Rhythm Pharmaceuticals From Rhythm Pharmaceuticals ( RYTM )   we learned that positive, top-line results from two pivotal Phase 3 clinical trials evaluating setmelanotide,   for pro-opiomelanocortin ( POMC ) and leptin receptor ( LEPR ) deficiency obesities, have met...

Read More

August 7, 2019

0

INmune Bio: A Novel Approach Towards Treating Alzheimer's Disease

Alzheimer's Disease Alzheimer’s Disease has proven very difficult to treat through many of the trials’ attempts by both small and large biotechnology and biopharmaceutical companies. Analysts and investors are skeptical about all promised successes in defeating this disease. However,  knowing...

Read More

July 14, 2020

0

Pfizer and BioNTech Vaccine Candidate Against COVID-19 Achieved a Sweet Success

Pfizer and BioNTech Good News Regarding COVID-19 Vaccine Candidate Pfizer ( PFE ) and BioNTech ( BNTX ) announced that their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 (the virus that causes COVID-19) has demonstrated evidence of efficacy against COVID-19 in...

Read More

November 9, 2020

0

  • Previous
  • 1
  • 2
  • ...
  • 84
  • 85
  • 86
  • ...
  • 115
  • 116
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy